Childrens Mercy - Kansas City

Patients that have residual leukemia stem cells after chemotherapy and other treatments have substantially higher risk for relapse. Survival rates for relapsed leukemia are very poor. Even when patients survive long-term, the very toxic anti-cancer treatments are escalated in treating relapsed leukemia. This particularly risks long-term health and substantially increases the risk of early death due to side-effects of the treatment itself. John Perry, PhD, faculty member of the Children's Research Institute at Children's Mercy Kansas City is studying how leukemia stem cells resist current anti-cancer treatments. Join us for this podcast as Dr. Perry discusses the promise of low-dose doxorubicin as a targeted therapy against leukemia stem cells rather than a broadly toxic chemotherapy drug.